




The relative strengths and weaknesses of Theravance Biopharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Theravance Biopharma Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 329% points. The greatest weakness of Theravance Biopharma Inc is the variable Other Assets, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is 675%, being 430% points above the market average of 245%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	353,464	Assets	607,400
Cost of Goods Sold	0	Liabilities	28,715
Intangible Assets	0	Expenses	149,681
Liabilities, Current	28,715	Revenues	51,346
Liabilities, Non-Current	0	Stockholders Equity	578,685
Other Assets	242,061	Net Income	872,132
Other Compr. Net Income	-15	Comprehensive Net Income	872,124
Other Expenses	19,216	BaseVar	903,812
Other Liabilities	0	ECR before LimitedLiability	671%
Other Net Income	970,467	Economic Capital Ratio	675%
Other Revenues	51,346		
Property and Equipment	11,875		
Research and Development	63,392		
Selling, General and Administrative Expense	67,073		